Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 44 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR PDX Mouse Models Are Reliable Stand-Ins for Human Tumors, Study Finds February 2, 2021 Exercising While Living With Peripheral Neuropathy: What People Diagnosed With Cancer... May 2, 2023 EMA Recommends Granting a Marketing Authorisation for Retifanlimab February 26, 2024 Topical Diclofenac Gel Reduces the Incidence of Hand-Foot Syndrome in Patients... March 6, 2024 Load more HOT NEWS Single-Fraction SABR Preferred from Resource and Patient Perspectives for Pulmonary Oligometastases Encouraging Single-Agent Antitumour Activity of Divarasib Across KRAS G12C-positive Tumours Lo que deben saber las personas con cáncer de mama y... One in Five of Older Patients with EBC Treated in a...
